


β-Aminoarteether maleate

Cat. No.:	HY-137553A
CAS No.:	133162-25-1
Molecular Formula:	C ₂₁ H ₃₃ NO ₉
Molecular Weight:	443.49
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	β-Aminoarteether maleate (SM934) is an Artemisinin derivative with orally active. β-Aminoarteether maleate can be used for inflammation and autoimmune disease research, such as lupus diseases ^[1] .								
In Vitro	β-Aminoarteether (SM934; 10 μM; 24 hours) treatment directly enhances IL-10 production and suppresses IL-12/23p40 production in primary peritoneal macrophages with IFN-γ stimulation ^[1] . In vitro, β-Aminoarteether (SM934) could suppress the Th1 and Th17 polarization, but exerted no influence on Treg differentiation ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	β-Aminoarteether (SM934; 1-10 mg/kg; oral administration; daily; for 3 months) treatment significantly delays the progression of glomerulonephritis and increases the survival rate of NZB/W F1 mice. β-Aminoarteether treatment promotes the IL-10 production of macrophages from NZB/W F1 mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>Female NZB/W F1 mice (Six and half months old)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>1 mg/kg, 3 mg/kg, and 10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral administration; daily; for 3 months</td> </tr> <tr> <td>Result:</td> <td>Significantly delayed the progression of glomerulonephritis and increased the survival rate of NZB/W F1 mice.</td> </tr> </table>	Animal Model:	Female NZB/W F1 mice (Six and half months old) ^[1]	Dosage:	1 mg/kg, 3 mg/kg, and 10 mg/kg	Administration:	Oral administration; daily; for 3 months	Result:	Significantly delayed the progression of glomerulonephritis and increased the survival rate of NZB/W F1 mice.
Animal Model:	Female NZB/W F1 mice (Six and half months old) ^[1]								
Dosage:	1 mg/kg, 3 mg/kg, and 10 mg/kg								
Administration:	Oral administration; daily; for 3 months								
Result:	Significantly delayed the progression of glomerulonephritis and increased the survival rate of NZB/W F1 mice.								

REFERENCES

[1]. Li-Fei Hou, et al. SM934 treated lupus-prone NZB × NZW F1 mice by enhancing macrophage interleukin-10 production and suppressing pathogenic T cell development. PLoS One. 2012;7(2):e32424.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA